Chronic spontaneous urticaria is defined as persistent symptoms of urticaria for 6 weeks or more. It is associated with autoimmunity in approximately 45 percent of patients. Therapy is often...
Study 114 of Cobicistat from Gilead Sciences reported a primary endpoint analysis that indicated that after 48 weeks of treatment,...
For the treatment of pruritus, eczema, dermatitis, and scaling skin conditions where an antipruritic and/or hydrating effect is required. It may also be used for the continued treatment and follow-up treatment of these skin diseases.
Shionogi announced positive results from two identically-designed 12 week phase III studies (COMPOSE I and II) demonstrating consistent efficacy and...
Biogen announced positive top-line results from CONFIRM, the second of two pivotal Phase III clinical trials designed to evaluate the...
Merck has announced results from a Phase III study investigating the safety and efficacy of single-dose Emend (fosaprepitant dimeglumine) for...
Amgen announced results from the Xgeva (denosumab) Phase III '482 study, the largest international multiple myeloma trial for the prevention...
Genentech a member of the Roche Group announced that data from the Phase III GiACTA study, which evaluated Actemra(tocilizumab) in...